US · SNOA
Sonoma Pharmaceuticals, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Woodstock, GA 30189
- Website
- sonomapharma.com
Price · as of 2025-03-31
$1.20
Market cap 5.02M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $1,012.80 | +84,300% |
| Intrinsic Value(DCF) | $1.33 | +10.83% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $10,836.00 | $26,199.86 | $4.93 | $0.00 | $0.00 |
| 2012 | $4,347.00 | $5,409.27 | $24.12 | $0.00 | $0.00 |
| 2013 | $3,123.00 | $144,193.25 | $349.87 | $0.00 | $0.00 |
| 2014 | $2,862.00 | $209,460.26 | $171.39 | $968.71 | $0.00 |
| 2015 | $1,215.00 | $3,426.43 | $26.51 | $0.00 | $0.00 |
| 2016 | $864.00 | $396.87 | $0.00 | $0.00 | $2,694.41 |
| 2017 | $1,260.00 | $5,777.62 | $93.56 | $1,444.66 | $8,562.31 |
| 2018 | $685.80 | $2,484.89 | $0.00 | $0.00 | $0.00 |
| 2019 | $140.40 | $346.62 | $0.02 | $0.00 | $0.00 |
| 2020 | $188.00 | $4,945.84 | $0.00 | $0.00 | $0.00 |
| 2021 | $159.00 | $1,574.81 | $0.00 | $0.00 | $0.00 |
| 2022 | $65.00 | $76.20 | $1.52 | $0.00 | $434.59 |
| 2023 | $28.00 | $64.54 | $0.00 | $0.00 | $0.00 |
| 2024 | $4.20 | $854.77 | $0.00 | $0.00 | $0.00 |
| 2025 | $3.32 | $1,012.80 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Sonoma Pharmaceuticals, Inc.'s (SNOA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $1,012.80
- Current price
- $1.20
- AI upside
- +84,300%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.33
+10.83% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SNOA | Sonoma Pharmaceuticals, I… | $1.20 | 5.02M | +84,300% | +11% | — | — | -1.19 | 0.93 | 0.29 | 0.27 | — | 0.93 | 38.25% | -25.97% | -24.20% | -65.55% | -250.76% | -24.32% | 0.07 | — | 3.09 | 2.23 | 1.42 | -4756.00% | 1219.00% | -9304.00% | -4.08% | -0.02 | -11.36% | 0.00% | 0.00% | 61.89% | 0.26 | 5.65 | -0.07 | -19.06 |
| BFRI | Biofrontera Inc. | $0.91 | 10.62M | +16,739% | -59% | — | — | -0.29 | 1.14 | 0.14 | -0.28 | — | 1.15 | 50.12% | -46.14% | -47.61% | -384.98% | -281.81% | -70.99% | 1.11 | -8.17 | 1.72 | 0.93 | 0.07 | -7527.00% | 949.00% | -5851.00% | -203.55% | -0.85 | -169.15% | 0.00% | 0.00% | 99.29% | -0.24 | -0.40 | 0.11 | -7.68 |
| EVOK | Evoke Pharma, Inc. | $11.00 | 18.95M | +308% | +3,860,968% | — | — | -1.38 | 1.05 | 0.72 | 0.22 | — | 1.05 | 96.52% | -50.77% | -52.22% | -240.09% | 280.01% | -43.54% | 0.73 | -10.38 | 1.66 | 1.54 | 1.74 | -8995.00% | 9784.00% | 950.00% | -73.85% | -0.53 | 293.71% | 0.00% | 0.00% | 117.66% | 0.20 | 0.19 | -0.10 | -9.79 |
| FLGC | Flora Growth Corp. | $7.79 | 4.23M | +647% | +31% | — | +112% | -19.62 | 69.19 | 5.24 | -20.59 | — | -1289.54 | 21.00% | -26.73% | -26.73% | -291.50% | -345.04% | -63.82% | 1.09 | -74.68 | 1.05 | 0.71 | 0.07 | -8226.00% | -2178.00% | -3964.00% | -1.66% | -0.27 | -113.30% | 0.00% | 0.00% | 0.14% | -19.55 | -60.19 | 5.23 | 0.49 |
| MYNZ | Mainz Biomed B.V. | $0.76 | 3.11M | +29,917% | +195% | — | — | -0.25 | 0.90 | 6.08 | -0.13 | -0.02 | 1.79 | 64.31% | -2091.23% | -2421.80% | -465.82% | -559.63% | -151.15% | 0.54 | -17.39 | 1.32 | 1.08 | 0.15 | 128025.00% | -17.00% | -2724.00% | -319.32% | -2.87 | -519.21% | 0.00% | 0.00% | 61.01% | -0.13 | -0.14 | 2.76 | -13.59 |
| QNRX | Quoin Pharmaceuticals, Lt… | $8.37 | 4.92M | — | — | — | — | -0.16 | 0.16 | — | 1.34 | — | 0.17 | 0.00% | — | — | -121.13% | 192.82% | -64.60% | 0.00 | — | 3.57 | 3.36 | 0.38 | -8019.00% | — | -9.00% | -540.58% | -1.88 | 159.01% | 0.00% | 0.00% | 84.08% | 1.32 | 1.60 | — | -5.96 |
| RADX | Radiopharm Theranostics L… | $4.99 | 6.43M | +1,761% | — | — | — | — | 1.36 | 16.76 | -0.83 | — | -34.17 | 1.08% | -1050.63% | -1055.27% | 0.00% | -302.69% | 0.00% | 0.00 | -584.59 | 2.67 | 2.65 | 0.76 | -8533.00% | 111427.00% | 5950.00% | -60.17% | -2.45 | -290.58% | 0.00% | — | 17.31% | -0.83 | -0.87 | 8.75 | -2.59 |
| TCRT | Alaunos Therapeutics, Inc… | $3.19 | 7.12M | +18,244% | -80% | — | — | -0.55 | 1.26 | 259.40 | -0.32 | — | 1.26 | 100.00% | -48120.00% | -46790.00% | -111.80% | -790.80% | -84.93% | 0.00 | — | 3.98 | 1.58 | 0.23 | -8671.00% | 10000.00% | -8362.00% | -191.63% | -7.18 | -816.93% | 0.00% | 0.00% | 0.00% | -0.31 | -0.30 | 150.30 | -470.35 |
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
- CEO
- Amy Trombly
- Employees
- 10
- Beta
- 1.66
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.33 ÷ $1.20) − 1 = +10.83% (DCF, example).